Market closed
Enliven Therapeutics, Inc./$ELVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Ticker
$ELVN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
62
ISIN
US29337E1029
Website
ELVN Metrics
BasicAdvanced
$904M
-
-$1.89
1.15
-
Price and volume
Market cap
$904M
Beta
1.15
52-week high
$22.69
52-week low
$13.30
Average daily volume
344K
Financial strength
Current ratio
19.989
Quick ratio
19.695
Management effectiveness
Return on assets (TTM)
-21.87%
Return on equity (TTM)
-32.04%
Valuation
Price to book
2.91
Price to tangible book (TTM)
2.91
Price to free cash flow (TTM)
-11.839
Growth
Earnings per share change (TTM)
-6.09%
3-year earnings per share growth (CAGR)
-15.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Enliven Therapeutics, Inc. stock?
Enliven Therapeutics, Inc. (ELVN) has a market cap of $904M as of May 10, 2025.
What is the P/E ratio for Enliven Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Enliven Therapeutics, Inc. (ELVN) stock is 0 as of May 10, 2025.
Does Enliven Therapeutics, Inc. stock pay dividends?
No, Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Enliven Therapeutics, Inc. dividend payment date?
Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. (ELVN) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.